Adamis Pharmaceuticals Current Assets

Adamis Pharmaceuticals posts a current assets of $7.9B as of September 2023. That compares with $10M in the prior-year period — up 77932.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Adamis Pharmaceuticals's current assets was $10M. The latest reading is $7.9B — a 77932.9% year-over-year increase (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Adamis Pharmaceuticals's financial statement story. At $7.9B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ADMP's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Adamis Pharmaceuticals's other metric pages and overview cover the third.

Judging Adamis Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $7.9B here, then scan peer and history charts to see if the gap is persistent.